연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
1457. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH.
J Cancer Res Clin Oncol. 2014 Feb;140(2):227-33. doi: 10.1007/s00432-013-1548-4. Epub 2013 Dec 1.
Link
1456. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification.
Kim H, Park S, Lee HK, Chung J.
Exp Mol Med. 2013 Sep 27;45:e43. doi: 10.1038/emm.2013.83.
Link
1455. Reporter gene imaging.
Youn H1, Chung JK.
AJR Am J Roentgenol. 2013 Aug;201(2):W206-14. doi: 10.2214/AJR.13.10555.
Link
1454. cAMP signalling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via Epac and p38 MAPK in lung cancer cells.
Jeong MJ1, Kim EJ, Cho EA, Ye SK, Kang GH, Juhnn YS.
FEBS Lett. 2013 May 2;587(9):1373-8. doi: 10.1016/j.febslet.2013.03.010. Epub 2013 Mar 20.
Link
1453. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW1, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15.
Link
1452. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW1, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15.
Link
1451. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B1, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY.
Ann Surg Oncol. 2013 Jul;20(7):2242-9. doi: 10.1245/s10434-012-2756-x. Epub 2013 Mar 26.
Link
1450. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
Kim JW1, Cho HJ, Kim M, Lee KH, Kim MA, Han SW, Oh DY, Lee HJ, Im SA, Kim TY, Yang HK, Kim WH, Bang YJ.
Cancer Chemother Pharmacol. 2013 Jun;71(6):1435-43. doi: 10.1007/s00280-013-2141-x. Epub 2013 Apr 30.
Link
1449. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Min A1, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, O'Connor MJ, Kim WH, Bang YJ.
Mol Cancer Ther. 2013 Jun;12(6):865-77. doi: 10.1158/1535-7163.MCT-12-0950. Epub 2013 Mar 19.
Link
1448. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B1, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
Breast Cancer. 2013 Apr;20(2):167-73. doi: 10.1007/s12282-011-0323-0. Epub 2012 Feb 7.
Link